GHK-Cu: Copper Tripeptide Complex Research Summary

Overview

GHK-Cu is a naturally occurring tripeptide-copper complex of glycyl-L-histidyl-L-lysine, first isolated from human plasma by Loren Pickart in 1973. Endogenous plasma concentrations decline significantly with age.

It is widely used under the INCI name 'Copper Tripeptide-1' in anti-ageing, skin-remodelling and hair products. In systemic therapeutic contexts it remains purely investigational — it is not registered on the Australian Register of Therapeutic Goods for systemic administration and is monitored as an unapproved peptide by the TGA. Silverback Peptides supplies it for laboratory research only.

Mechanism of Action

GHK-Cu functions as a high-affinity carrier of divalent copper (Cu2+), forming a stable complex with a formation constant (log K) of approximately 16.2–16.4. The copper ion sits in a square-planar coordination, bound by the histidine imidazole nitrogen, the N-terminal glycine amino group, and the deprotonated glycine–histidine peptide nitrogen.

Research literature describes several pathways through which the complex acts:

• Extracellular-matrix remodelling — stimulates collagen (types I and III), elastin and glycosaminoglycan synthesis in dermal fibroblasts, and increases decorin expression.
• Gene-expression modulation — transcriptomic studies report broad modulation of gene expression, upregulating DNA-repair and antioxidant pathways.
• Angiogenesis — increases VEGF and bFGF expression, promoting capillary sprouting.
• Anti-inflammatory activity — suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in activated immune cells.

Key Published Studies

In full-thickness dermal wound models in rats, topical or systemic GHK-Cu accelerated wound contraction, re-epithelialisation and granulation-tissue formation. In diabetic wound models, GHK-Cu-impregnated collagen dressings markedly increased collagen synthesis versus saline controls.

A 2025 animal study in Frontiers in Pharmacology reported that systemic GHK-Cu promoted mucosal healing in a model of ulcerative colitis by upregulating tight-junction proteins and suppressing inflammatory cytokines. Small human studies in chronic venous and diabetic ulcers have reported reductions in local inflammatory markers with topical GHK-Cu formulations.

Storage & Handling

Lyophilised GHK-Cu appears as a blue crystalline powder. Store at 2–8°C or −20°C in a desiccated container, protected from light. Once reconstituted with sterile or bacteriostatic water, store at 2–8°C.

The complex is most stable in mildly acidic to neutral conditions (pH 5.0–6.5). A colour shift away from deep blue indicates copper dissociation and loss of integrity.